Comparing anti-VEGFs for DME

Article

In a 1-year comparison of intravitreous aflibercept, bevacizumab and ranibizumab therapy for centre-involved DME, aflibercept was more effective at improving vision among patients who started treatment at lower levels of visual acuity.

In a 1-year comparison of intravitreous aflibercept, bevacizumab and ranibizumab therapy for centre-involved diabetic macular oedema (DME), aflibercept was more effective at improving vision among patients who started treatment at lower levels of visual acuity. In patients with milder baseline levels of visual acuity loss, however, there were no differences, on average, between the three medications.

As published in the New England Journal of Medicine, the Diabetic Retinopathy Clinical Research Network randomly assigned 660 adults with DME involving the macular centre to receive 2.0 mg of intravitreous aflibercept (224 participants), 1.25 mg of bevacizumab (218 participants), or 0.3 mg of ranibizumab. The study took place at 89 clinical sites. Following a protocol-specified algorithm, drugs were administered as often as every 4 weeks.

The researchers used a mean visual-acuity letter score for their analysis. Higher scores on a range of 1 to 100 indicate better visual acuity, with a score of 85 indicating approximately 20/20 vision.

From baseline to 1 year, the mean visual-acuity letter score improved by 13.3 among patients who received aflibercept, by 11.2 among patients who received ranibizumab, and by 9.7 among patients who received bevacizumab.

The researchers noted, however, that despite the apparent greater improvement with aflibercept, the driver was eyes with worse visual acuity at baseline, making the difference not clinically meaningful. Among the 51% of participants who had a baseline initial visual-acuity letter score of 78 to 69, the mean improvement was 8.3 with ranibizumab, 8.0 with aflibercept, and 7.5 with bevacizumab.

Among patients who had an initial letter score of less than 69, the mean improvement was 18.9 with aflibercept, 14.2 with ranibizumab, and 11.8 with bevacizumab.

The researchers concluded that “intravitreous aflibercept, bevacizumab, and ranibizumab were effective and relatively safe treatments for DME causing vision impairment,” and that “when initial visual-acuity loss was mild, there was, on average, little difference in visual acuity at 1 year among the three agents. However, at worse levels of initial visual acuity, aflibercept was more effective at improving vision.”

To read the full study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.